<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00734435</url>
  </required_header>
  <id_info>
    <org_study_id>OZ-101</org_study_id>
    <nct_id>NCT00734435</nct_id>
  </id_info>
  <brief_title>Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects</brief_title>
  <official_title>A Proof of Concept, Multi-Center, Randomized, Double-Blind, Parallel, Placebo-Controlled, Study of Zonisamide Sustained Release (SR) 360 mg Versus Placebo in the Prevention of Weight Gain Associated With Olanzapine Therapy for Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if zonisamide SR will prevent weight gain in&#xD;
      schizophrenic subjects who take olanzapine (Zyprexa)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor Decision- Financial Considerations&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in total body weight</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Schizophreniform Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 360 mg and olanzapine 10-20 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and olanzapine 10-20 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zonisamide SR plus olanzapine</intervention_name>
    <description>zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo plus olanzapine</intervention_name>
    <description>Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects,18-55 years of age&#xD;
&#xD;
          -  Outpatients diagnosed with schizophrenia, schizoaffective disorder, or&#xD;
             schizophreniform disorder&#xD;
&#xD;
          -  Body mass index (BMI) between 22-35 kg/m2 (inclusive)&#xD;
&#xD;
          -  Negative serum pregnancy test in women of child-bearing potential&#xD;
&#xD;
          -  If women of child-bearing potential, must be non-lactating and agree to use an&#xD;
             acceptable form of contraception, which in all cases, includes one type of barrier&#xD;
             method, throughout the study period and for 30 days after discontinuation of study&#xD;
             drug&#xD;
&#xD;
          -  Subject requires a change in antipsychotic treatment and olanzapine is deemed by the&#xD;
             Investigator to be a reasonable antipsychotic treatment choice&#xD;
&#xD;
          -  No clinically significant abnormality on ECG&#xD;
&#xD;
          -  No clinically significant laboratory abnormality&#xD;
&#xD;
          -  Negative urine drug screen&#xD;
&#xD;
          -  Must be considered reliable and possess a level of understanding that enables the&#xD;
             subject to provide written informed consent and to comply with protocol procedures and&#xD;
             schedule&#xD;
&#xD;
          -  Must be able to read and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of substance dependence within the 6 months prior to randomization&#xD;
&#xD;
          -  diagnosis of substance abuse (except for nicotine and caffeine) within the 3 months&#xD;
             prior to randomization&#xD;
&#xD;
          -  Suicidal behavior or ideation within 3 months prior to randomization, or any current&#xD;
             suicidal ideation or intent&#xD;
&#xD;
          -  Presence of dementia or other organic brain syndrome&#xD;
&#xD;
          -  Serious or unstable medical illnesses&#xD;
&#xD;
          -  Known, uncorrected narrow-angle glaucoma&#xD;
&#xD;
          -  Diagnosis of eating disorder as defined by DSM-IV within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Require treatment with any typical or atypical antipsychotic in addition to olanzapine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Breier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larue D. Carter Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>American Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald Maguire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCI Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zinoviy Benzar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooklyn Medical Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohammed Bari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synergy Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tran Johnson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNRI</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eduard Gfeller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Clinical Research Center, Maitland Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Cutler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Clinical Research Center, Bradenton Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Riesenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atlanta Center for Medical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synergy Research</name>
      <address>
        <city>National City</city>
        <state>California</state>
        <zip>91950</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCI Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNRI San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clincal Research Center</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Clinical Research Center</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>34208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Medical Research</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larue D. Carter Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Medical Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <disposition_first_submitted>November 27, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2012</disposition_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>schizophreniform</keyword>
  <keyword>schizoaffective disorder</keyword>
  <keyword>Zyprexa</keyword>
  <keyword>olanzapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Weight Gain</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

